Analysts at Mizuho began coverage on shares of Pfizer (NYSE:PFE) in a report issued on Monday, The Fly reports. The brokerage set a “buy” rating and a $38.00 price target on the biopharmaceutical company’s stock. Mizuho’s target price would indicate a potential upside of 16.21% from the company’s previous close.
Several other research analysts also recently commented on PFE. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 target price on the stock. in a research note on Monday, May 4th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $53.00 target price on shares of Pfizer in a research note on Thursday, March 19th. Piper Sandler lifted their target price on shares of Pfizer from $18.50 to $24.00 in a research note on Friday, June 26th. Morgan Stanley decreased their target price on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 2nd. Finally, SVB Leerink initiated coverage on shares of Pfizer in a research note on Tuesday, June 16th. They issued a “market perform” rating and a $40.00 target price on the stock. Ten research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and an average price target of $38.72.
PFE stock opened at $32.70 on Monday. The company has a market capitalization of $181.31 billion, a PE ratio of 11.68, a price-to-earnings-growth ratio of 2.51 and a beta of 0.70. Pfizer has a one year low of $27.88 and a one year high of $44.56. The company’s 50 day moving average price is $35.60 and its two-hundred day moving average price is $36.28. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.78 and a current ratio of 1.02.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.71 by $0.09. The firm had revenue of $12.03 billion for the quarter, compared to the consensus estimate of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. The business’s revenue was down 8.3% compared to the same quarter last year. During the same period last year, the firm posted $0.85 earnings per share. On average, research analysts predict that Pfizer will post 2.88 EPS for the current year.
In other news, EVP Douglas M. Lankler sold 65,000 shares of the business’s stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $37.85, for a total transaction of $2,460,250.00. Following the sale, the executive vice president now owns 135,375 shares in the company, valued at approximately $5,123,943.75. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Jennifer B. Damico sold 2,181 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $36.13, for a total transaction of $78,799.53. Following the sale, the senior vice president now owns 7,542 shares in the company, valued at approximately $272,492.46. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 69,362 shares of company stock worth $2,622,691. Company insiders own 0.08% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. New England Investment & Retirement Group Inc. bought a new position in Pfizer in the 1st quarter worth about $26,000. Lion Street Advisors LLC bought a new position in Pfizer in the 1st quarter worth about $27,000. Benjamin Edwards Inc. boosted its stake in Pfizer by 49.8% in the 1st quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 335 shares in the last quarter. Disciplined Investments LLC boosted its stake in Pfizer by 43.3% in the 1st quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 347 shares in the last quarter. Finally, Efficient Wealth Management LLC bought a new position in Pfizer in the 1st quarter worth about $50,000. Hedge funds and other institutional investors own 70.28% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: What is Put Option Volume?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.